Overview
- Elutia said it submitted the 510(k) for the base matrix NXT-41 on March 11 and anticipates FDA clearance in the second half of 2026, with NXT-41x clearance targeted in the first half of 2027.
- Management outlined a commercialization plan that projects an NXT-41x launch in the second half of 2027, subject to regulatory clearance.
- The company began a process to explore strategic options for its SimpliDerm line to focus time and capital on the upcoming NXT-41x rollout.
- Elutia strengthened launch readiness by adding Chief Commercial Officer Pete Ligotti and appointing Guido J. Neels to its board.
- An $88 million sale of the BioEnvelope business to Boston Scientific funded full repayment of the $26.9 million SWK loan and left $36.4 million in cash plus $8.0 million in escrow at year-end 2025.